aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $25.67 Average PT from Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $25.6667.

ATYR has been the topic of a number of research reports. Wall Street Zen upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th.

aTyr Pharma Price Performance

Shares of NASDAQ:ATYR opened at $0.75 on Wednesday. The company’s fifty day moving average price is $0.87 and its 200-day moving average price is $0.97. The firm has a market capitalization of $73.73 million, a price-to-earnings ratio of -0.95 and a beta of 0.55. aTyr Pharma has a one year low of $0.64 and a one year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. As a group, equities research analysts expect that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG raised its stake in shares of aTyr Pharma by 158.1% during the third quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock worth $3,249,000 after acquiring an additional 2,760,238 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of aTyr Pharma by 272.2% in the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock valued at $2,060,000 after purchasing an additional 1,923,907 shares in the last quarter. Millennium Management LLC boosted its stake in shares of aTyr Pharma by 334.5% in the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after purchasing an additional 1,231,052 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of aTyr Pharma by 126.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company’s stock valued at $10,639,000 after purchasing an additional 1,170,276 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of aTyr Pharma by 21.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock valued at $4,060,000 after purchasing an additional 975,887 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.